Kairos Pharma Ltd
kairospharma.comWhat Do They Do?
Develops drug candidates, including antibodies and small molecules, to treat prostate, lung, breast and brain cancers.
10-K for FY2025, filed Mar 31, 2026We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in…View ↗
Our product portfolio currently consists of:View ↗
We have sought to develop a broad portfolio of novel and transformative drug therapies to treat cancer. Our current portfolio consists of…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$1.4MView ↗
- ▼ −2% (Loss)
- vs −$1.4M in Q2 FY2025
-
Jun 4, 2026
Signed a term sheet to acquire rights to CL-741
The proposed rights cover an oral candidate for lung, esophageal and gastric cancers.
Sources
8-K, filed Jun 4, 2026
As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates…View ↗
Loading...
